A pilot clinical trial in the US has found a new immunotherapy treatment to be safe in people with new onset type 1 diabetes (T1D).
After clinical presentation of T1D, beta cell loss continues progressively in most people until C-peptide levels, a marker of endogenous insulin production, is absent or present in very low levels. Despite intensive research efforts for more than 20 years, no therapy is currently available to prevent beta cell loss in T1D.
TrialNet is an international collaborative network that aims to prevent, delay and reverse the progression of type 1 diabetes, involving United States, Canada, Finland, United Kingdom, Italy, Germany, Australia and New Zealand.
TrialNet in Australia/New Zealand is led by A/Prof John Wentworth at Walter & Eliza Hall Institute (WEHI) in collaboration with Prof Peter Colman AM.
Giving probiotics to babies in the first few weeks of life may lower their risk of developing type 1 diabetes, a recent study has found.
The study, published in JAMA Pediatrics found that children who were given probiotics within the first 27 days of life had a 60% reduction in the risk of developing islet autoimmunity, compared with children who were first given probiotics after 27 days or not at all. Read More
The Australian Type 1 Diabetes Clinical Research Network has partnered with the Immune Tolerance Network to launch a new Australian clinical trial to slow the development of newly diagnosed type 1 diabetes in children.
The EXTEND-P trial is expected to begin recruitment in March 2016 to test the ability of an existing drug called tocilizumab to preserve beta cell function. Tocilizumab, sold under the brand name Actemra, is currently approved for use in children with juvenile arthritis. Read More
JDRF International in collaboration with the American Diabetes Association (ADA) has published a new classification system for identifying and defining the early, pre-clinical stages of type 1 diabetes (T1D).
Our immune systems vary with the seasons, according to a study led by the University of Cambridge that could help explain why conditions such as type 1 diabetes are more frequently diagnosed during the winter months.
The study, funded by JDRF, the Wellcome Trust and the NIHR Cambridge Biomedical Research Centre was published today in the journal Nature Communications. The study shows that the activity of almost a quarter of our genes (5,136 out of 22,822 genes tested) differs according to the time of year, with some more active in winter and others more active in summer. This seasonality also affects our immune cells and the composition of our blood and fat tissue.
Scientists have known for some time that various diseases, including autoimmune diseases such as type 1 diabetes and multiple sclerosis, display seasonal variation. However, this is the first time that researchers have shown that this may be down to seasonal changes in how our immune systems function. Read More